Gepirone Vs Placebo in Treatment of Cocaine Dependence - 3

This study has been completed.

First Received: September 20, 1999 Last Updated: June 23, 2005 History of Changes

Sponsor:	National Institute on Drug Abuse (NIDA)
Collaborator:	University of Pennsylvania
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00000189

Purpose

The purpose of this study is to test antidepressant medication, gepirone, as a pharmacotherapy for cocaine dependent subjects.

Condition	Intervention	Phase
Cocaine-Related Disorders	Drug: Gepirone	Phase II

Study Type:	Interventional
Study Design:	Treatment
Official Title:	Gepirone Vs Placebo in Treatment of Cocaine Dependence

Resource links provided by NLM:

Drug Information available for: Gepirone

U.S. FDA Resources

Further study details as provided by National Institute on Drug Abuse (NIDA):

Estimated Enrollment:

Eligibility

Genders Eligible for Study:	Male
Accepts Healthy Volunteers:	No

Criteria

Please contact site for information.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000189

Locations

United States, Pennsylvania
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104 6178

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

University of Pennsylvania

Investigators

Principal Investigator:

James Cornish, M.D.

University of Pennsylvania

More Information

No publications provided

Study ID Numbers:	NIDA-00144-3, K20-00144-3
Study First Received:	September 20, 1999
Last Updated:	June 23, 2005
ClinicalTrials.gov Identifier:	NCT00000189 History of Changes
Health Authority:	United States: Federal Government

Additional relevant MeSH terms:

Serotonin Agonists
Cocaine-Related Disorders
Neurotransmitter Agents
Tranquilizing Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Psychotropic Drugs
Disorders of Environmental Origin
Central Nervous System Depressants

Pharmacologic Actions
Gepirone
Serotonin Agents
Mental Disorders
Therapeutic Uses
Substance-Related Disorders
Anti-Anxiety Agents
Central Nervous System Agents
Antidepressive Agents

ClinicalTrials.gov processed this record on November 27, 2009